BOSTON--(BUSINESS WIRE)--Feb 29, 2012-- SciFluor Life Sciences, a drug discovery and development company harnessing the transformational power of fluorine to accelerate the development of innovative new therapeutics, today announced an agreement with Harvard University that extends its license of proprietary fluorine technology to the rapidly growing field of Positron Emission Tomography (PET) imaging.

Under the new agreement, SciFluor gains access to technology that enables the rapid, efficient synthesis of 18F-labeled molecules that empower PET imaging for an entirely new level of intelligent, informed and predictive drug development. The company previously announced an exclusive, worldwide license from Harvard University to various fluorination methods and to a portfolio of novel fluorinated compounds.

"We are pleased to further expand the breadth of our innovative fluorine technologies and to extend our licensing agreement with Harvard," said Arthur Hiller, chief executive officer of SciFluor Life Sciences. "With this new technology, SciFluor is now capable of developing sophisticated 18F PET tracers that were previously inaccessible. This advance paves the way to significantly expand the capabilities of PET imaging in the drug discovery and development process by providing researchers with new insights into a drug candidate's potential efficacy, safety and optimal dosing. Our initial focus will be on identifying industry partnerships between SciFluor and companies with drug pipelines and research priorities that benefit from applying this fluorination technology, which ultimately could result in shorter development times, improved clinical trial designs and more revolutionary therapies for patients." PET is a non-invasive imaging modality that allows researchers and physicians to view how organs and tissues in the body are functioning at the molecular and cellular levels during early stages of disease progression. PET imaging is frequently used to diagnose a wide range of cancers and additional clinical applications are rapidly emerging in neurological disorders and cardiovascular disease. By utilizing SciFluor technology in PET imaging, researchers will now be able to observe a broader range of a drug's cellular and metabolic activity in vivo to determine, for example, the drug's capacity to cross the blood-brain barrier, its ability to hit the relevant biological targets, and ultimately, the drug's dose effectiveness and potential clinical benefit.

This newly-licensed technology was recently described in the paper, "A Fluoride-Derived Electrophilic Late-Stage Fluorination Reagent for PET Imaging" published in the Nov. 4, 2011,issue of Scienceand co-authored by Tobias Ritter, Ph.D., founder and chief technology officer of SciFluor.

"We are delighted to place this technology with SciFluor, an emerging leader in the field of fluorination technology," said Isaac Kohlberg, senior associate provost and head of Harvard's Office of Technology Development. "Our mission is to promote the public good by fostering innovation and translating new inventions made at Harvard into useful products beneficial to society. We are pleased to grant this new license to SciFluor, which reinforces and advances that mission." About SciFluor Life Sciences, LLC SciFluor is harnessing the transformational power of fluorine to enrich pipelines, optimize drug discovery and accelerate the clinical development of innovative new therapies. The company's approach includes a proprietary portfolio of FluoropeuticsTM, fluorine-enabled development candidates targeting a broad range of therapeutic indications; breakthrough fluorine chemistry technology that enables the fluorination of a wide variety of drugs at any stage of development; and novel 18Ftracers for empowered PET imaging. SciFluor is funded by Allied Minds, a private equity-funded innovation company that forms, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs.

The company was founded in 2011 and is based in Boston, Mass. For more information, please visit

About Allied Minds, Inc.

Allied Minds is a private equity-funded innovation company that forms, funds, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs. We serve as a diversified holding company that supports our businesses with capital, management and shared services. Allied Minds is the premier firm to utilize this novel and fully-integrated approach to technology commercialization. Our investments span multiple business sectors and offer an attractive risk-return profile, a deliverable timeline and groundbreaking products and services. Our subsidiaries include Allied Minds Devices, BA Logix, Biotectix, Cephalogics, CryoXtract, Illumasonix, ProGDerm, Precision Biopsy, RF Biocidics, SaltCheck, SciFluor Life Sciences, SiEnergy Systems, SoundCure, and Spin Transfer Technologies. We don't just fund the startup. We are the startup. About Harvard University's Office of Technology Development The Harvard Office of Technology Development (OTD) is responsible for all activities pertaining to the evaluation, patenting and licensing of new inventions and discoveries made at Harvard University and Harvard Medical School. OTD also serves to further the development of Harvard technologies through the establishment of sponsored research collaborations with industry. OTD's mission is to promote the public good by fostering innovation and translating new inventions made at Harvard into useful products available and beneficial to society.

CONTACT: Pure Communications, Inc.